Melanoma Patients’ and Clinicians’ Satisfaction with Telehealth During COVID-19

Not Applicable

Completed

• Conditions: Melanoma; Cancer - Malignant melanoma

• Registration Number: ACTRN12620001167954
• Lead Sponsor: Melanoma Institute Australia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-11-06
• Study Completion: 2022-03-01
• Last Update Posted: 13 February 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 115

Inclusion Criteria

Patients:
- 18 years of age.
- Able to read and understand English and respond to study questions
- Cognitive capacity to provide informed consent.
- Diagnosis of melanoma (any stage).
- Participation in at least on telehealth consultation in relation to their melanoma since March 2020.
- Receiving services from healthcare professionals at one of the study sites.

Clinicians
- Healthcare professional (e.g. doctor, nurse, allied health) involved in providing care, support, and management of patients with melanoma.
- Providing services within the study sites that are approved for this study.
- Provision of at least one telehealth consultation in relation to melanoma management since March 2020.

Exclusion Criteria

Patients:
- Younger than 18 years of age.
- Insufficient English and/or cognitive ability to understand and respond to study materials.
- Diagnosis of any other skin condition, including non-melanoma skin cancer
- Participation in telehealth. consultations that are not related to melanoma management.

Clinicians
- Practicing outside the approved study sites.
- Providing only face to face consultations during COVID-19 (since March 2020)
- Not involved in care of melanoma patients.
- Participation in an interview as a part of ‘The Management of Primary Melanoma in the Time of COVID-19; Lessons and Future Directions’

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patients' satisfaction with telehealth, which is a composite primary outcome, measured by: <br>- Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)<br>- 4 additional satisfaction questions that have been previously used in research <br>- 5 satisfaction qualitative questions that will be analysed for emerging themes [At the time of survey completion ];Clinicians' satisfaction with telehealth, which is a composite primary outcome, as measured by: <br>- Health Optimum Telemedicine Acceptance Questionnaire<br>- Additional 9 quantitative satisfaction questions previously used in research<br>- five qualitative questions that will be analysed for emerging themes [At the time of survey completion ]

Secondary Outcome Measures

Name	Time	Method
Trust in oncologist, measured using Trust in Oncologist Scale (TiOS-SF)<br>[At the time of survey completion];- Quality of life, measured using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Version 3 (EORTC QLQ-C30) and Melanoma Concerns Questionnaire (MCQ-28)<br>[At the time of survey completion];- Fear of Cancer Recurrence, measured using Fear of Cancer Recurrence Inventory- Short Form (FCRI-SF)[At the time of survey completion ];Suitability of Medicare items for telehealth consultations in melanoma, as measured by 4 qualitative questions that have been designed specifically for this study[At the time of survey completion ]